Outcomes | Anticipated absolute effects*(95% CI) | Relative effect (95% CI) | № of participants (studies) | Certainty of the evidence (GRADE) | Comments | |
---|---|---|---|---|---|---|
Risk with placebo | Risk with erenumab | |||||
Reduction in migraine days follow up: 3–6 months | The mean reduction in migraine days was −1.9 days | The mean reduction in migraine days in the intervention group was 1.2 days fewer (1.8 fewer to 0.5 fewer) | – | 1455 (3 RCTs) | ⨁⨁⨁⨁ HIGH | Treatment with erenumab 70 mg results in reduction in migraine days compared with placebo. |
Reduction in use of acute attack medication follow up: 3–6 months | The mean reduction in use of acute attack medication was −0.6 days | The mean reduction in use of acute attack medication in the intervention group was 0.8 days fewer (1.3 fewer to 0.4 fewer) | – | 1455 (3 RCTs) | ⨁⨁⨁⨁ HIGH | Treatment with erenumab 70 mg results in reduction in use of acute attack medication compared with placebo. |
Improvement in functional MPFID everyday-activities follow up: 3–6 months | The mean improvement in functional MPFID everyday-activities was −3.3 points | The mean improvement in functional MPFID everyday-activities in the intervention group was 2.2 points lower (3.3 fewer to 1.2 fewer) | – | 628 (1 RCT) | ⨁⨁⨁◯ MEDIUMa | Treatment with erenumab 70 mg results in improvement in functional MPFID everyday-activities score compared with placebo. |
At least 50% reduction in days of migraine follow up: 3–6 months | 283 per 1000 | 422 per 1000 (366 to 488) | RR 1.4918 (1.2925 to 1.7217) | 1441 (3 RCTs) | ⨁⨁⨁⨁ HIGH | Treatment with erenumab 70 mg results in at least 50% reduction of days of migraine compared with placebo. |
Serious adverse events follow up: 3–6 months | 17 per 1000 | 17 per 1000 (8 to 37) | RR 0.9992 (0.4590 to 2.1752) | 1464 (3 RCTs) | ⨁⨁⨁⨁ HIGH | Treatment with erenumab 70 mg results in a small possibly unimportant effect in serious adverse events occurrence compared with placebo. |
Mortality follow up: 3–6 months | 0 per 1000 | 0 per 1000 (0 to 0) | Not estimable | 1464 (3 RCTs) | No deaths occurred during the double-blind treatment phase of the trial. |